Taking stock of the drug industry, from the lab to the medicine chestFebruary 16, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Aera Therapeutics STAT+ | CRISPR pioneer Feng Zhang launches new genetic delivery startup with $193 million The startup's technology has the potential to address significant limitations with gene editing treatments and mRNA therapies. By Allison DeAngelis STAT+ | Republicans are using the FTC's Lina Khan as an excuse for opposing drug pricing bills Congress' efforts to get more information on the business practices of pharmacy benefit managers are running into an unlikely roadblock. By John Wilkerson STAT+ | Key Senate committee takes first step toward tackling health workforce shortages Senate HELP kicked off the new Congress with one of the rare subjects both its leaders agree on: addressing health workforce shortages. By Sarah Owermohle Molly Ferguson for STAT Can food be medicine? Will insurers cover it? And other big questions about a new health movement There's new enthusiasm in Washington for using healthy food as a medical intervention for chronic diseases. By Nicholas Florko Researchers link certain genes to obesity complications in women The genes indicated a high waist-to-hip ratio in women, which is a better predictor of cardiovascular risk than body mass. By Elaine Chen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments